Jenscare Scientific Co. Ltd. has announced promising results from its recent studies on two innovative medical devices. The 30-day follow-up results from the global multicenter clinical trial of the LuX-Valve Plus transcatheter tricuspid valve replacement, known as the TRINITY study, as well as the one-year follow-up data from the JensClip transcatheter mitral valve repair system, were unveiled at EuroPCR 2025 in Paris. The findings indicate that 96.3% of patients experienced no regurgitation above moderate levels. Additionally, improvements were noted in various indicators such as the New York Heart Association cardiac function, Kansas City Cardiomyopathy Questionnaire scores, and six-minute walking distance. Jenscare Scientific aims to continue advancing the application and commercialization of these products globally, although it cautions that there is no guarantee of ultimate success in development and marketability.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。